Health ❯ Healthcare ❯ Drug Development
FDA Approval Regulatory Approval Phase 3 Trials Real-World Evidence Phase 2 Trials Phase III Trials Targeted Therapy Eli Lilly Side Effects Investigational Therapies Alzheimer's Disease Orforglipron Innovative Therapies Semaglutide Phase 1 Trials Weight Loss Treatments AI in Medicine Amyloid Immunotherapy Epinephrine Alternatives Tumor-Infiltrating Lymphocytes Alzheimer's Disease Treatments Regulatory Exclusivity Biosimilar Approval Process Leqembi GBT-601 Pharmaceutical Innovations Neuropharmacology Neurodegenerative Diseases Randomized Controlled Trials Market Dynamics CAPLYTA Late-Stage Studies Weight-loss Medications Repurposed Medications Gene Therapy Innovations Antibiotic Resistance CNS Disorders Combination Therapies mRNA Vaccines Alzheimer's Treatments Oncology Camizestrant Immunology Treatments NHS Innovations Immunology Preclinical Research Market Trends Neuropsychiatric Drugs Bronchodilators Chronic Lung Conditions Wegovy Monoclonal Antibodies Safety Monitoring Pain Relief Medications Cancer Pain Relief Cancer Treatments Efficacy Studies Gilead Sciences Lung Disease Drugs Phase III Studies Phase 3 Clinical Studies Lecanemab Weight Loss Medications Future Research Directions Generic Versions Metabolic Disease Therapies Expanded Access Programs Nuzolvence Post-Marketing Studies Cancer Medications Obesity Drug Candidates Next-Gen Therapies Adverse Drug Reactions Weight Loss Therapies Selective Estrogen Receptor Degraders Regulatory Submissions Therapeutic Applications Focal Segmental Glomerulosclerosis PALOMA-3 Trial Oncology Assets Vaccine Trials Investigational Drugs Azer-cel Pediatric Autoimmune Conditions Therapeutic Products Psoriasis Treatments Efficacy of Treatments Study Requirements Single Study Approval Obesity Therapies Orexin Receptor Agonists Approval Processes Phase 1 Studies Precision Medicine Anti-Amyloid Drugs Phase 2b Trials Phase I Trials Anito-cel Therapeutics Phase 3 Studies
Want to see what podcasts are saying about this topic? Search across 145K+ podcasts. Explore Radar
Because the Phase 1 candidate engaged its target but failed to show clinical benefit, the company will shift to proprietary programs to stretch cash into the second half of 2029.
